Essential Hypertension: Current Needs and Methodological Problems with Non-pharmacological Treatment

  • P. R. Jackson
  • W. W. Yeo
  • L. E. Ramsay
Conference paper
Part of the Current Topics in Cardiovascular Diseases book series (2943)

Abstract

Epidemiological studies have shown that a significant proportion of the population have diastolic blood pressures above 100 mmHg even on rechecking. Trials from many countries demonstrate that treatment of such patients with hypotensive drugs reduces the risk of stroke, heart failure and renal failure.1,2,3,4 The benefit in terms of a reduced risk of myocardial infarction is smaller but an overview of the trials shows that even this disorder may be reduced by about 14%.5 Thus, the detection and treatment of people with high blood pressure represents one of the major challenges in the prevention of cardiovascular disease. Reduction in blood pressure may be achieved by means other than drug treatment such as weight loss, restricting excess alcohol intake and cutting back on salt consumption. Further benefit may be gained by getting patients to quit smoking thus preventing added cardiovascular damage. In normal practice pharmacological treatment would only be initiated if the blood pressure remains elevated despite such measures.

Keywords

Placebo Stratification Washout Atenolol Ketanserin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    European Working Party: Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly Trial. Lancet 1985; 1: 1349Google Scholar
  2. 2.
    The Management Committee: The Australian therapeutic trial in mild hypertension. Lancet 1980; 1: 1261Google Scholar
  3. 3.
    Medical Research Council Working Party: MRC trial of treatment of mild hypertension: principal results. Br. Med. J. 1985; 191: 97Google Scholar
  4. 4.
    Veterans Administration Cooperative Study Group: Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressure averaging 90 through 114mmHg JAMA 1970; 213: 1143Google Scholar
  5. 5.
    Collins R., Peto R., MacMahon S. et al.: Blood pressure, stroke, and coronary heart disease. 2: Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827PubMedCrossRefGoogle Scholar
  6. 6.
    Intersalt Cooperative Research Group: Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24hr urinary sodium and potassium excretion. Br. Med. J. 1988; 297: 319CrossRefGoogle Scholar
  7. 7.
    Watt G.C.M., Edwards C., Hart J.T., Hart M., Walton P., Foy C.J.W.: Dietary sodium restriction for mild hypertension in general practice. Br. Med. J. 1983; 286: 432CrossRefGoogle Scholar
  8. 8.
    Endres S., Ghorboni R., Kelley V.E. et al.: The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin I and tumor necrosis factor by mononuclear cells. New Engl. J. Med. 1989; 320 (5): 265–271Google Scholar
  9. 9.
    Armitage P.: Should we cross off the crossover ? Br. J. Clin. Pharmac. 1991; 32: 1CrossRefGoogle Scholar
  10. 10.
    Chaput de Saintonge D.M., Evans S.J.W., Vere D.W.: Statistical methods in clinical trials. In Recent Advances in Clinical Pharmacology, London, Edinburgh, Churchill Livingstone 1990; 19–34Google Scholar
  11. 11.
    O’Brien E., Mee F., Atkins F., O’Malley K.: Inaccuracy of the Hawksley random zero sphygmomanometer. Lancet 1990; 2: 1465CrossRefGoogle Scholar
  12. 12.
    Armitage P., Rose G.A.: The variability of measurements of casual blood pressure. Clin. Sci. 1966; 30: 325PubMedGoogle Scholar
  13. 13.
    Altman D.G.: Statistics and ethics in medical research. III. How large a sample ? Br. Med. J. 1980; 281: 1336PubMedCrossRefGoogle Scholar
  14. 14.
    Freestone S., Silas J.H., Ramsay L.E.: Sample size for short-term trials of antihypertensive drugs. Br. J. Clin. Pharmac. 1982; 14: 265CrossRefGoogle Scholar
  15. 15.
    Bristol D.R.: Sample sizes for constructing confidence intervals and testing hypotheses. Statistics in Medicine. 1989; 8: 803PubMedCrossRefGoogle Scholar
  16. 16.
    Cameron H.A., Waller P.C., Ramsay L.E.: Ketanserin in essential hypertension: use as monotherapy and in combination with a diuretic or 13-adrenoceptor antagonist. Br. J. Clin. Pharmac. 1987; 24: 705CrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 1992

Authors and Affiliations

  • P. R. Jackson
    • 1
  • W. W. Yeo
    • 1
  • L. E. Ramsay
    • 1
  1. 1.University Department of Medicine and TherapeuticsRoyal Hallamshire HospitalSheffieldUK

Personalised recommendations